Literature DB >> 29674761

Impact of Body Mass Index on Survival of Pancreatic Cancer Patients in Japan.

Tomohiro Okura1, Masakuni Fujii, Junji Shiode, Yuri Ito, Toru Kojima, Junichiro Nasu, Takefumi Niguma, Masao Yoshioka, Tetsushige Mimura, Kazuhide Yamamoto.   

Abstract

The impact of body mass index (BMI) on postoperative survival in Japanese patients with pancreatic cancer is unclear. We examined the relationship between preoperative BMI and the prognosis of Japanese patients who underwent surgery for pancreatic cancer to determine whether BMI affects these patients' prognosis. Of the patients who underwent pancreatectomy between January 2004 and August 2015 at our institution, 246 were pathologically diagnosed with pancreatic tubular adenocarcinoma; the cancer was located in the pancreatic head (n=161) and in the body and tail (n=85). We classified the patients by BMI: underweight (n=22), normal weight (n=190), and overweight/obese (n=34) groups. We retrospectively analyzed medical records for patient characteristics, lesion location, disease stage, postoperative complications, chemotherapy, and prognosis. Lesion location, disease stage, postoperative complications, and chemotherapy were not significantly different among the BMI groups. The median survival times were as follows (days): all patients, 686; underweight, 485; normal weight, 694; and overweight/obese, 839. In a multivariate analysis, after adjusting for competing risk factors, low BMI was associated with an increased risk of death (normal weight: HR 0.58, p=0.038; overweight/obese: HR 0.54, p=0.059). High BMI was not found to be a postoperative factor for poor prognosis in Japanese pancreatic cancer patients.

Entities:  

Keywords:  BMI; pancreatic cancer; prognosis; risk factor; surgery

Mesh:

Year:  2018        PMID: 29674761     DOI: 10.18926/AMO/55853

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  3 in total

1.  The Association Between BMI and Mortality in Surgical Patients.

Authors:  Idit Dotan; Tzipora Shochat; Ilan Shimon; Amit Akirov
Journal:  World J Surg       Date:  2021-01-22       Impact factor: 3.352

2.  Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study.

Authors:  Jinbo Shi; Xiawei Li; Yulian Wu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-06-25

3.  Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients.

Authors:  Ningzhen Fu; Yu Jiang; Kai Qin; Hao Chen; Xiaxing Deng; Baiyong Shen
Journal:  BMC Cancer       Date:  2021-12-09       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.